Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) have been given an average rating of “Moderate Buy” by the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.40.
A number of equities analysts have weighed in on the company. Maxim Group lowered their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 8th. B. Riley lowered Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Finally, HC Wainwright lowered their price objective on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th.
Check Out Our Latest Stock Analysis on Actinium Pharmaceuticals
Hedge Funds Weigh In On Actinium Pharmaceuticals
Actinium Pharmaceuticals Stock Performance
Shares of ATNM opened at $1.72 on Friday. The firm has a 50 day simple moving average of $1.86. The firm has a market capitalization of $51.23 million, a price-to-earnings ratio of -1.01 and a beta of 0.14. Actinium Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $10.24.
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, analysts anticipate that Actinium Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
Featured Articles
- Five stocks we like better than Actinium Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Energy and Oil Stocks Explained
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What does consumer price index measure?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.